Jakarta, CNBC Indonesia – In the midst of the ongoing pandemic situation, globally, the market is still struggling to gain momentum amid continued uncertainty surrounding the risks that Omicron could pose to the economy.
At the opening of trading Thursday (2/12/2021), European markets also tended to weaken with continued anxiety about the variant of the Omicron Covid-19 virus amid the efforts of the blue continent countries which are fighting the latest wave of infections.
Meanwhile, the majority of stock markets in Asia Pacific – including the JCI – turned higher even though there were still concerns about the new variant.
Even though the JCI was able to close in the green zone, the market was still watching the news about the new strain of Covid-19 Omicron and how it affected the global economy. Currently, a number of countries are tightening travel regulations from other countries as they accelerate the acceleration of vaccination.
World Health Organization (WHO) officials said 24 countries had recorded cases of the Omicron variant so far. But some early indications or symptoms are mostly mild and none are classified as severe. The WHO also said 23 countries had reported cases of the Omicron variant so far.
In the last five trading days, the JCI recorded a correction of 1.56%, while the health sector index was able to grow 1.40% in the same period.
This increase is reasonable considering that when the pandemic conditions get worse, stocks from the health sector will be hunted by investors, as previously happened when the delta variant hit the middle of this year.
The complicated conditions of the pandemic can directly affect the financial performance of health companies, be it from increasing sales of test kits, drugs or increasing inpatients in hospitals.
So, which stocks of pharmaceutical issuers have cheap and attractive valuations to buy?
Here, the CNBC Indonesia Research Team presents a list of the top 5 LQ45 stocks with the cheapest valuations.
– .
